increased risk of death, serious cardiovascular events, and vascular access thrombosis was observed when erythropoiesis-stimulating agents (ESAs) were administered to target a haemoglobin of greater ic
halálozás, súlyos kardiovaszkuláris események, valamint a vérnyerőhelynél kialakuló thrombosis gy